HK Innoen Holds Symposium to Commemorate Launch of Diabetes Treatment 'Dapaen'

HK Innoen held the 'Simshindangbu Dapaen Symposium' to announce the market launch of 'Dapaen,' a sodium-glucose co-transporter (SGLT)-2 inhibitor class diabetes treatment.

On the 6th, speakers are conducting a Q&A session at the 'Simshindang Dapaen Launching Symposium' held at the InterContinental COEX Hotel in Gangnam-gu, Seoul.
[Photo by HK Innoen]

On the 10th, HK Innoen announced that it held the 'Simshindangbu Dapaen Launching Symposium' on the 6th at the InterContinental COEX Hotel in Gangnam-gu, Seoul, to commemorate the launch of the Dapaen series, an SGLT-2 inhibitor containing dapagliflozin. The symposium was conducted in an interactive talk show format with about 3,000 medical professionals from various specialties participating both online and offline.

The Simshindangbu Dapaen Launching Symposium was named by taking the first letters of ‘Simjang-en’ (for heart), ‘Sinjang-en’ (for kidney), ‘Dangnyo-en’ (for diabetes), and ‘Buga-jeogin Ijeom-en’ (for additional benefits), reflecting the characteristics of dapagliflozin. HK Innoen introduced the single formulation ‘Dapaen Tablets 10 mg’ along with the combination formulations of dapagliflozin and metformin, ‘Dapaen Duo Extended-Release Tablets 5/1000, 10/500, 10/1000 mg,’ to offer various treatment options depending on the patient's condition. HK Innoen plans to first release Dapaen Tablets in line with the expiration of related patents and to launch Dapaen Duo Extended-Release Tablets on the 1st of next month after completing the procedures related to National Health Insurance coverage.

The symposium was chaired by Professor Changbeom Lee of the Department of Endocrinology and Metabolism at Hanyang University Guri Hospital and Professor Chulyoung Park of the Department of Endocrinology at Kangbuk Samsung Hospital. Speakers from four specialties?cardiology, nephrology, endocrinology, and family medicine?participated. The event began with a lecture by Professor Junhwa Hong of the Department of Endocrinology at Daejeon Eulji University Hospital on the overall features and advantages of dapagliflozin. This was followed by Professor Jongyoung Lee of the Department of Cardiology at Kangbuk Samsung Hospital, who discussed how dapagliflozin can be used in patients with heart failure and cardiovascular diseases. Professor Yongcheol Kim of the Department of Nephrology at Seoul National University Hospital lectured on the use cases and safety of dapagliflozin in patients with varying severities of kidney disease. Finally, Professor Yangim Heo of the Department of Family Medicine at Bundang CHA Hospital spoke about the additional benefits of SGLT-2 inhibitors. The symposium provided an opportunity to exchange information on the unique advantages and real-world cases of dapagliflozin across different medical fields.

Professor Changbeom Lee, who chaired the symposium, expressed his expectations, saying, “We look forward to the active role of dapagliflozin, which can manage not only diabetes but also heart and kidney diseases.” HK Innoen CEO Dalwon Kwak also stated, “Dapaen and Dapaen Duo Extended-Release Tablets will expand the choices available to medical professionals while providing convenience in medication for diabetes patients.”

The SGLT-2 inhibitor market is growing annually as it shows efficacy not only in diabetes but also in chronic heart failure and chronic kidney disease. Among these, the dapagliflozin segment was estimated to be worth about 90 billion KRW in outpatient prescription sales last year.

This content was produced with the assistance of AI translation services.